Abstract
Recent clinical studies have reported an increased risk for various types of cancers in patients with diabetes. Diabetes is characterized by increased oxidative stress conditions. Hyperglycemia induces oxidative stress generation in a variety of cells via various metabolic pathways, thus causing oxidative DNA damage, an initial step of carcinogenesis. There is accumulating evidence that advanced glycation end products (AGE), senescent macroprotein derivatives formed at an accelerated rate under normal aging process and diabetes, are involved in the development and progression of cancers. AGE stimulate oxidative stress generation through the interaction with a receptor for AGE (RAGE), while oxidative stress generation promotes the formation of AGE and increases the expression of RAGE. These findings suggest that the crosstalk between the AGE-RAGE system and oxidative stress generation may form a positive feedback loop, thus further increasing the risk for cancers in patients with diabetes. This paper reviews current knowledge about the role of AGE-RAGE system in the development of various types of cancers.
Keywords: AGE, RAGE, oxidative stress, angiogenesis
Current Pharmaceutical Design
Title: AGE-RAGE System and Carcinogenesis
Volume: 14 Issue: 10
Author(s): Riichiro Abe and Sho-ichi Yamagishi
Affiliation:
Keywords: AGE, RAGE, oxidative stress, angiogenesis
Abstract: Recent clinical studies have reported an increased risk for various types of cancers in patients with diabetes. Diabetes is characterized by increased oxidative stress conditions. Hyperglycemia induces oxidative stress generation in a variety of cells via various metabolic pathways, thus causing oxidative DNA damage, an initial step of carcinogenesis. There is accumulating evidence that advanced glycation end products (AGE), senescent macroprotein derivatives formed at an accelerated rate under normal aging process and diabetes, are involved in the development and progression of cancers. AGE stimulate oxidative stress generation through the interaction with a receptor for AGE (RAGE), while oxidative stress generation promotes the formation of AGE and increases the expression of RAGE. These findings suggest that the crosstalk between the AGE-RAGE system and oxidative stress generation may form a positive feedback loop, thus further increasing the risk for cancers in patients with diabetes. This paper reviews current knowledge about the role of AGE-RAGE system in the development of various types of cancers.
Export Options
About this article
Cite this article as:
Abe Riichiro and Yamagishi Sho-ichi, AGE-RAGE System and Carcinogenesis, Current Pharmaceutical Design 2008; 14 (10) . https://dx.doi.org/10.2174/138161208784139765
DOI https://dx.doi.org/10.2174/138161208784139765 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical Trials
Current Cancer Drug Targets Malignant Intracranial High Grade Glioma and Current Treatment Strategy
Current Cancer Drug Targets Modulation of Nitric Oxide Pathway by Multiligands/RAGE Axis: A Crossing Point on the Road to Microvascular Complication in Diabetes
Current Enzyme Inhibition Novel Fluorine Boron Hybrid Complex as Potential Antiproliferative Drugs on Colorectal Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Emerging Therapeutic Targets and Agents for Glioblastoma Migrating Cells
Anti-Cancer Agents in Medicinal Chemistry Targeting Multiplicity: The Key Factor for Anti-Cancer Nanoparticles
Current Medicinal Chemistry An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry Characterization of Molecular and Functional Alterations of Tumor Endothelial Cells to Design Anti-Angiogenic Strategies
Current Vascular Pharmacology Human Growth Hormone Induced Cholestatic Hepatitis in a Growth Hormone Deficient Patient with Short Stature
Current Drug Safety Update on Pharmacologic Retinal Vascular Toxicity
Current Pharmaceutical Design TGF-beta Signaling in Cancer Treatment
Current Pharmaceutical Design Targeting Ion Channels in Leukemias: A New Challenge for Treatment
Current Medicinal Chemistry Focus on the Role of Glutamate in the Pathology of the Peripheral Nervous System
CNS & Neurological Disorders - Drug Targets Effects of LPA and S1P on the Nervous System and Implications for Their Involvement in Disease
Current Drug Targets Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses
Current Pharmaceutical Biotechnology Current Understanding of Epigenetics Driven Therapeutic Strategies in Colorectal Cancer Management
Endocrine, Metabolic & Immune Disorders - Drug Targets Apoptosis Induction by Erucylphosphohomocholine via the 18 kDa Mitochondrial Translocator Protein: Implications for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Current Pharmaceutical Design Targeting the Phosphatidylinositol 3-Kinase/AKT Pathway for the Treatment of Multiple Myeloma
Current Medicinal Chemistry The PI3K/Akt Pathway: Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors
Current Cancer Drug Targets